Medicare coverage for GLP-1 weight-management medications has been one of the most-watched healthcare policy developments of 2026. For the 67 million Americans enrolled in Medicare, the coverage landscape is evolving — and the implications are significant.
The Current State of Medicare GLP-1 Coverage
Historically, Medicare Part D has not covered weight-loss medications. This exclusion dates back to the Medicare Modernization Act of 2003, which specifically prohibited Part D coverage for drugs used for weight loss.
However, the landscape has shifted in several important ways. The Treat and Reduce Obesity Act and related legislative efforts have advanced through Congress. Some Medicare Advantage plans have begun offering supplemental coverage for obesity medications. The Centers for Medicare and Medicaid Services (CMS) has issued guidance that opens pathways for coverage in specific clinical scenarios.
Diabetes vs Weight Management
Medicare Part D does cover GLP-1 medications prescribed for type 2 diabetes — Ozempic (semaglutide) and Mounjaro (tirzepatide) are covered under the diabetes indication. The coverage gap primarily affects patients seeking GLP-1 prescriptions for weight management without a diabetes diagnosis.
What Has Changed in 2026
Several developments have expanded Medicare GLP-1 access:
- Medicare Advantage supplemental benefits: A growing number of Medicare Advantage plans now include obesity medication coverage as a supplemental benefit. Check with your specific MA plan during open enrollment.
- Cardiovascular indication pathway: Following the SELECT trial results showing cardiovascular risk reduction with semaglutide, some Medicare plans are covering GLP-1 therapy under a cardiovascular disease prevention indication rather than weight loss — which sidesteps the statutory exclusion.
- Legislative momentum: Bipartisan bills addressing Medicare obesity medication coverage continue to advance. While full statutory coverage has not yet been enacted, the political trajectory suggests eventual expansion.
How Medicare Beneficiaries Can Access GLP-1s Now
Through Diabetes Coverage
If you have a type 2 diabetes diagnosis, your Medicare Part D plan covers GLP-1 medications under the diabetes indication. The weight-loss benefit comes as a clinical effect of the diabetes treatment.
Through Medicare Advantage Supplemental Benefits
If your Medicare Advantage plan offers obesity medication coverage, follow the standard PA process through your plan.
Through Self-Pay
Medicare beneficiaries can choose to pay out of pocket for compounded GLP-1 medications through telehealth platforms. This bypasses the Medicare coverage question entirely.
Sesame Care From $99/visit · Prescribes FDA-approved brand-name medications only. Accepts insurance. No subscription lock-in.
Prescribes FDA-approved brand-name medications only.
Eden Health $239/mo sema · Physician-led telehealth. Semaglutide from $239/mo. Free consultation, ongoing clinical support, cancel anytime.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
Direct Meds From $175/mo · Direct-to-patient GLP-1 prescriptions. Board-certified prescribers. Fast turnaround.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
What to Watch For
The trajectory of Medicare GLP-1 coverage points toward expansion. The economic evidence increasingly supports coverage — the cost of treating obesity-related complications (cardiovascular disease, diabetes, joint replacements) far exceeds the cost of obesity pharmacotherapy. Monitor your Medicare Advantage plan's formulary updates and congressional action on obesity medication coverage.
If you are a Medicare beneficiary considering self-pay for GLP-1 medications, be aware that these out-of-pocket costs do not count toward your Medicare Part D out-of-pocket maximum. You are paying entirely outside the Medicare system.